Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PAPPA encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). Additionally we are shipping PAPPA Kits (49) and PAPPA Proteins (20) and many more products for this protein.
Showing 10 out of 400 products:
Human Monoclonal PAPPA Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN191313
Qin, Christiansen, Pettersson: Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for Down syndrome. in Clinical chemistry 2002
Human Monoclonal PAPPA Primary Antibody for IA, IP - ABIN268232
Pan, Hanada, Zhao, Mao, Ma: Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo. in PLoS ONE 2012
Intrinsic mitochondrial oxidative capacity was significantly increased in skeletal muscle of aged PAPP-A KO compared to WT mice. Moreover, 18-month-old PAPP-A KO mice exhibited significantly enhanced endurance running on a treadmill. Thus, PAPP-A deficiency in mice is associated with indices of healthy skeletal muscle function with age.
Snell, GHKRO, and PAPPA-KO mice express high levels of two proteins involved in DNA repair, O-6-methylguanine-DNA methyltransferase (MGMT (show MGMT Antibodies)) and N-myc downstream-regulated gene 1 (NDRG1 (show NDRG1 Antibodies)).
STC2 (show STC2 Antibodies) is involved in regulating PAPP-A activity during the development of atherosclerosis
Study demonstrates proof-of-principle and provides feasibility for a novel therapeutic strategy to inhibit atherosclerotic plaque burden by selective targeting of PAPP-A.
stimulation of PAPP-A expression by intermittent PTH (show PTH Antibodies) treatment contributes to PTH (show PTH Antibodies) bone anabolism in mice
PAPP-A affects fascicle structure, thereby affecting tendon phenotype.
PAPP-A has a role in development of advanced plaque with necrotic cores and buried fibrous caps (show CAPS Antibodies) in the brachiocephalic artery
these data indicate preferential impact of PAPP-A deficiency on visceral fat in the mouse that is associated with enhanced insulin receptor (show INSR Antibodies) signaling
Studies show a conditional PAPP-A knockout (KO) model for efficacy of tamoxifen-induced floxed PAPP-A excision in various tissues and indicate a significant reduction of neointimal formation after unilateral carotid artery ligation.
absence of PAPP-A is associated with resistance to the development of indicators of diabetic nephropathy in mice
Elevated PAPP-A compared to other risk factors was a stronger predictor for future CV events 2 years post ACS in patients with type 2 diabetes mellitus.
PAPP-A, like CCS (show CCS Antibodies) and CIMT, is a parameter that can be used to detect subclinical atherosclerosis.
Results suggest that links between PAPP-A concentrations in early pregnancy and subsequent glucose concentrations and blood pressures may be mediated by changes in insulin (show INS Antibodies) sensitivity (and secretion).
Collectively, these results identify PAPP-A as a pregnancy-dependent oncogene (show RAB1A Antibodies) while also showing that extended lactation is protective against PAPP-A-mediated carcinogenesis.
Lower PlGF (show PGF Antibodies) and higher PAPP-A and free beta-hCG (show CGA Antibodies) levels were found in the fetal circulation of near-term severe preeclamptic pregnancies
PAPP-A 1224 SNP has a significant effect on the level and activity of PAPP-A in human follicles, suggesting that the follicular fluid level of bioactive insulin (show INS Antibodies)-like growth factor depends on the genotype.
This study demonstrated no association between PAPP-A gene rs7020782 polymorphism and Preeclampsia (PE) and intrauterine growth restriction.
data indicate that PAPP-A promotes TF expression in human endothelial cells and support the hypothesis that this proteinase, besides being involved in progression of atherosclerosis, does not represent an independent risk factor for adverse cardiovascular events, but it rather might play an "active" role in the pathophysiology of ACS as an effector molecule able to induce a pro-thrombotic phenotype in endothelial cells
assessed serum PAPP-A levels in COPD (show ARCN1 Antibodies) and the associations with disease severity; elevated levels of PAPP-A were observed in patients with COPD (show ARCN1 Antibodies)
study determined IGFR1 (show IGF1R Antibodies) and PAPP-A expression both in follicles at different stages of development and in ovarian cysts; data indicate that animals with cystic ovarian disease (COD (show SNRPB Antibodies)) have an altered regulation of the IGF system in the ovary and thus allow postulating IGFR1 (show IGF1R Antibodies) expression and PAPP-A secretion as a modulator of IGF1 (show IGF1 Antibodies) in cattle with COD (show SNRPB Antibodies)
in preovulatory follicles, PAPP-A is responsible for IGF-dependent IGFBP-2 (show IGFBP2 Antibodies) degradation
concluded that changes in granulosa cell PAPP-A mRNA levels do not occur during final preovulatory follicular development in cattle
This gene encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses.
IGF-dependent IGFBP-4 protease
, insulin-like growth factor-dependent IGF-binding protein 4 protease
, aspecific BCL2 ARE-binding protein 2
, differentially placenta 1 expressed protein
, insulin-like growth factor-dependent IGF binding protein-4 protease
, pregnacy-associated plasma protein A
, PAPPA-like protein
, pregnancy-associated plasma protein A-like protein
, cleaves insulin-like binding protein-4 (IGFBP-4)